Introduction
Human hepatocellular carcinoma (HCC),' although unusual in industrialized western countries, occurs with such frequency in the populous countries of sub-Saharan Africa and the Far East that on a global basis it constitutes one of the most highly prevalent tumors (1) . Unfortunately, because the onset of symptoms coincides with advanced stages of the disease, the prognosis is generally poor (2, 3). Once the tumor becomes widespread in the liver, surgical resection proves difficult and chemotherapeutic agents are relatively ineffective (3, 4) . An important goal would be to understand the characteristics of transformed hepatocytes better and pursue strategies for early in vitro and in vivo diagnosis.
In this regard, we have prepared several libraries of monoclonal antibodies against a newly developed (5) and other established HCC cell lines. Such antibodies have been tested for their specificity towards HCC, and several have been shown to recognize antigenic determinants that appear thus far almost exclusively on transformed hepatocytes. These antibodies, anti-HCC, have been employed in the construction of highly sensitive and specific radioimmunoassays that may detect "hepatoma-associated" antigens. In addition, one anti-HCC monoclonal antibody appears suitable for in vivo localization of tumor by nuclear imaging in a nude mouse system. The observed specificity of these antibodies, in conjunction with the characterization of their antigens, allow us to conclude that these antibodies will be useful in further clarifying the properties of transformed hepatocytes.
Methods
Hepatoma cell lines. PLC/PRF/5, SK Hep-l, and FOCUS HCC lines used for immunization of mice were maintained in Earle's modified Eagle's medium (M.A. Bioproducts, Walkersville, MD) supplemented with 10% fetal bovine serum inactivated at 560C, 10 MM nonessential amino acids, 1,000 U/ml of penicillin, and 100 Mg/ml of streptomycin. Cells were harvested from the monolayer cultures by washing three times with phosphate-buffered saline (PBS) followed by treatment with versene buffer in the absence of trypsin. Single cell suspensions thus obtained were used for immunization of BALB/c mice. All HCC cells were tested for mycoplasma by DNA staining and culture and found to be negative (kindly performed by the Mycoplasma Testing Laboratory, Massachusetts General Hospital).
Immunization and fusion protocols. Primary immunizations were accomplished with 4.0 X 106 cells/ml in 50% complete Freund's adjuvant and were injected intraperitoneally into female BALB/c mice. The secondary immunizations were performed 3 d before cell fusion by an intravenous inoculation of 4 .0 X 106 cells/200 Ml in PBS. The interval between primary and secondary immunizations varied between 6 and 10 wk. Splenocytes were fused with the NSl myeloma cell line. The maintenance and selection of hybridomas were as previously de- scribed (6) .
Selection of hybridomas with anti-HCC activity. Two radioimmunoassays (RIAs) were performed to identify hybridomas that produce HCC, human hepatocellular carcinoma; anti-HCC, antibodies to human hepatocellular carcinoma; HELF, human embryo lung fibroblast; PAGE, polyacrylamide gel electrophoresis.
antibodies with anti-HCC binding activity. In the first assay, 100,000 of the respective HCC target cells in 100 ul of Earle's modified Eagle's medium were incubated with 100 Ml of cell culture supernatant from 70% confluent hybridoma lines for I h at 370C. Cells were then washed three times with Hanks' balanced salt solution and resuspended between washings by gentle agitation followed by centrifugation at 1,200 rpm for 5 min. Resuspended cell pellets were subsequently incubated with 100,000 cpm '25l sheep antimouse F(ab')2 (New England Nuclear, Boston, MA) in 100 Mli of PBS with 1% bovine serum albumin for 0.5-1.0 h at 370C. In the second assay cells were grown on glass coverslips, washed three times with PBS, fixed via immersion into -80'C ethanol/acetone mixture (9:1), and incubated with 1:100 dilutions in PBS of ascites fluid preparations containing the For this procedure HCC cells were fixed to a solid-phase support as described (10) . '25I-labeled monoclonal anti-HCC antibodies (100,000 cpm) were incubated with increasing amounts of unlabeled homologous antibody to generate an inhibition curve. Next, the unlabeled homologous antibody was substituted for by a different unlabeled anti-HCC antibody and the counts per minute bound to the cells was determined at increasing antibody concentrations. If, for example, no inhibition of binding was observed under these conditions, we may presume that the second unlabeled antibody recognizes a separate and distinct determinant on HCC cells.
Identification ofcell surface antigens. Human hepatoma-associated cell surface antigens were partially characterized by using the method described by Soule et al. (11) . The HCC cells of a confluent 75-cm2 monolayer culture were radiolabeled with 125I by the lactoperoxidase method (12) . Subsequently, the cells were washed three times with icecold PBS and then solubilized in the flasks at 00C for 0.5 h by the addition of 3.0 ml of 1% Nonidet P-40, 20 mM Tris-HCI, pH 8.3, 140 mM NaCl, and 100 U trasylol/ml. The cell lysate was spun at 40,000 rpm for 30 min in a 50 Ti rotor to remove debris and then 0.5-ml aliquots of the supernatant were immunoprecipitated with individual anti-HCC antibodies by addition of 50 Ad of ascites fluid. Immune complexes were captured on fixed-killed Staph A cells (BoehringerMannheim Diagnostics, Houston, TX). These cell pellets were resuspended in 100 AI of SDS polyacrylamide gel electrophoresis (PAGE) buffer, heated at 100°C for 2.5 min, and then clarified at 1500 g for 5.0 min. The supernatant fractions were electrophoresed on a 10% polyacrylamide slab gel (13) . Gels were fixed, stained, destained, and/ or dried and autoradiographed for 12.0 h to 2.0 days by using Kodak x-ray film (Eastman Kodak Co., Rochester, NY).
Additional characterization of HCC-associated antigens was attempted when noniodinated cells were solubilized and centrifuged as described above. The clarified lysates were placed on affinity columns constructed with monoclonal anti-HCC antibodies bound to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals) at pH 7.4 for I h. The columns were then extensively washed with PBS, pH 2.6, and 4.0 M urea. 2-ml fractions were collected and assayed for binding activity by using the RIAs described above. Peak binding fractions were dialyzed against PBS and concentrated with a Micro devices Pro-Di-Con (Jenkintown, PA) (14 (5) and SK-Hep-l cells were prepared. 62 hybridoma cell lines producing anti-HCC antibodies to both FOCUS and SK-Hep-1 HCC cell lines were identified by high binding activity in the RIA (data not shown). Indeed, a primary immunization with intact cells followed by a maturation period of 6-10 wk before the second intravenous boost with a whole-cell suspension was found to be a successful schedule for production of anti-HCC antibodies.
The specificity of the antibodies was assessed by binding studies to a panel of cells as shown in Table I . These experiments allowed us to select antibodies of better-defined specificity for further characterization as described below. For Partial characterization of hepatoma-associated antigens.
Tests were performed with monoclonal anti-PLC antibodies for binding activity to a-fetoprotein, hepatitis B surface antigen (HBsAg), and carcinoembryonic antigen by using commercially available kits (Abbott Laboratories, No. Chicago, IL); there was no binding activity of the antibodies to these proteins.
In an attempt to define further the characteristics of the cell surface antigen(s), cell membrane proteins were radiolabeled by the lactoperoxidase method as previously described (15) .
Thus 1251 PLC/PRF/5, Mahlavu, HTC-41 (rat hepatoma) cells, and HELFs were studied. As shown by the autoradiographs in Fig. 3 , PM4E9917 precipitates a protein with a molecular weight of -65,000 (lane 1), whereas P215457 recognizes a cell surface protein of -50,000 mol wt (lane 3). Antibody P232524 did not precipitate a '251I-labeled cell surface membrane protein (lane 2). It is noteworthy that this antibody also did not stain the plasma membrane by immunofluorescence. Identical antigens with respect to molecular weight were identified on the Mahlavu cell line by PM4E9917 and P215457 (data not shown). Of considerable interest was the finding that the two proteins recognized by PM4E9917 and P215457 on PLC/ PRF/5 and Mahlavu human hepatoma cell lines were also detectable on the rat hepatoma cell surface membranes (lanes 6 and 9, respectively).
The specificity of the antigen-antibody interaction was demonstrated by the treatment of '25I-labeled cell membrane In vitro assays. After having identified and partially characterized hepatoma-associated cell surface proteins by anti-HCC monoclonal antibodies, studies were performed in an attempt to detect soluble antigens in cell culture supernatants derived from both human and rat hepatoma, as well as other nonhepatic human tumor cell lines. We developed, therefore, a series of RIAs that employed various combinations of antibodies PM4E9917, P232524, P241AE, P235F3, P29759, and P215457 both in a "simultaneous" and forward sandwich mode (9) . In general, the simultaneous sandwich assay design was found to be the optimal assay configuration with respect to sensitivity in a homologous system where the antibody bound to the solid-phase support and the radiolabeled indicator antibody are the same. High binding activity detected in culture supernatants derived from human hepatoma cell lines was only observed with PM4E9917, P232524, and P215457 monoclonal antibodies that used the simultaneous sandwich RIAs; we pursued the characteristics of the binding activity in greater detail. Similar observations were obtained with antibody P232524 by using an identical simultaneous sandwich homologous assay system, as shown in Fig. 5 . High binding activity was observed in cell culture supernatant from two HCC cell lines but not from control cells. Attempts were made to optimize the binding activity observed in the RIAs. Previous studies (Figs. 4 and 5) had established that near-maximal binding of antibody to antigen in the RIA was apparent after a 4-h incubation. Fig. 6 demonstrates that when using P215457 maximal binding activity occurs at 4°C. It is also apparent that the magnitude of binding activity is a direct function of temperature of incubation. It is somewhat surprising, however, that higher temperatures were associated with lower binding activity in the RIA. Fig. 6 also illustrates the specificity of P215457 for a human and/or rat hepatoma associated antigen(s) in cell culture supernatants.
It was of interest to isolate and characterize the binding activity in HCC cell culture supernatants, and we took advantage of the properties of antibodies P215457 and P232524. Thus, these two antibodies were coupled to cyanogen bromideactivated Sepharose 4B for isolation of antigenic activity by affinity chromatography. The affinity-purified and concentrated protein had been shown to have high binding activity in the RIAs before subjecting this material to SDS-PAGE. on the cell surface of both human and rat hepatoma cell lines (see Fig. 2 ). We were, however, unable to demonstrate an antigen by this technique with antibody P232524 (Fig. 7,  lane 3) . In vivo immunoassays. Monoclonal antibody P215457 was selected for in vivo imaging studies of HCC because of the following special properties: (a) the antibody demonstrated the highest binding activity to four human hepatoma cell lines (Table I) (Fig. 1) ; and (d) there was a sufficient concentration of P215457 in ascitic fluid (5-7 mg/ml) to prepare Fab fragment. Imaging of HCC may present several special problems because of its primary hepatic origin. Numerous attempts were made in the nude mouse system to image with "9mTc and "'In coupled to P215457 by diethylene triamine penta-acetic acid (DTPA). However, liver and spleen uptake of the conjugate was as high as that found in the tumor (data not shown). We therefore abandoned this approach and proceeded to perform imaging studies with '3'I-labeled P215457. [14] [15] [16] [17] [18] [19] [20] .tCi/pg). Imaging studies were performed at 6, 10, 12, 18, 24, 36, 48, and 72 h. Once the optimal conditions for imaging were established by preliminary studies, subsequent experiments were performed only at 10-and 24-h intervals. Fig. 8 depicts a representative radionuclide image using intact "'I-P215457 at 24 h. The tumor is well visualized. The blood pool, however, contains significant radioactivity (Fig. 8) . Under these conditions, it would be difficult to discriminate between normal liver, tumor, and the blood pool. Similar results were observed at later time periods, e.g., 36, 48, and 72 h (data not shown).
Biodistribution studies performed with the intact antibody at 24 h are shown in Table III . The highest radioactivity was present in the blood followed by tumor, spleen, and heart and in general confirm the radionuclide imaging results.
In the second set of studies, the experimental conditions were changed and attempts were made to image with the Fab fragment of P215457. This prepared fragment had a molecular weight of 45,000 on SDS-PAGE and appeared as a single protein band with little, if any, contamination with intact antibody or F(ab)2 fragment. In addition, the immunoreactivity of the Fab fragment was reevaluated by direct binding studies to PLC/PRF/5 cells in suspension before injection into the nude mouse that bore the tumor. The preparation of the Fab fragment resulted in an -10-fold reduction in immunoreactivity when compared to the native antibody (data not shown). Despite this significant reduction in immunoreactivity in vitro, Fig. 9 shows a representative serial imaging study with '3'IFab. In this experiment 50 gCi of '31I-P2 15457 Fab was injected into the tail vein. Fig. 9 B shows the nude mouse before imaging and demonstrates the size of the tumor. Fig. 9 A is an image of tumor localization at 10 h showing substantial uptake in the human hepatoma but a relatively high background blood pool. Fig. 9 C is the same mouse imaged at 24 h. There is a substantial improvement in tumor localization due to the clearance of '31I-Fab from the blood pool. Fig. 9 D is an image at 24 h of another animal bearing a nonhepatoma tumor in the left shoulder again demonstrating the specificity of '3'I-P215457 Fab for human hepatoma localization. Table III depicts the biodistribution of '31I-Fab in the various tissues. It was of interest that the uptake of '251-Fab in the tumor compared to normal liver and blood pool was 9:1 and 4:1, respectively. We speculate that the high uptake in the stomach may be due in part to dehalogenation of the Fab and concentrations of free 13'I in place of CL-in the lumen of the stomach during acid secretion.
Discussion
In the present investigation we have established several libraries of monoclonal antibodies directed towards antigenic determinants present on HCC cell lines to understand the properties of transformed hepatocytes better. We believe that the preparation of cells before immunization, the route of immunization, and the interval between primary and secondary immunizations were important features in establishing such antibodies with the desired properties for the development of experimental in vitro and in vivo immunoassays. Indeed, cells were removed from tissue culture dishes without proteolytic enzyme treatment in an attempt to preserve native cell surface antigenic determinants. Next, an interval of 6-10 wk was allowed between Table III ). primary and secondary immunization in an attempt to generate high affinity antibodies (6) . Most importantly, the secondary boost was accomplished intravenously with a nonproteolytic enzyme-treated single cell suspension. One disadvantage of the immunization protocol is the loss of immunized mice after the i.v. boost presumably due in part to the impediment of blood flow in the microcirculation by clumps of large human hepatoma cells.
It is noteworthy that others have produced monoclonal antibodies to HCC lines (6) . In one study, monoclonal antibodies to a HCC line designated Hep G-2 were produced after two intraperitoneal injections with trypsinized cells spaced 10 d apart. Two antibodies named 833-1C4 clone Gl and (18, 19) . (37, 38) . Similarly, we searched for the presence of hepatoma-associated antigenic determinants in cell culture supernatants from human and rat hepatoma and other tumor cell lines using the newly constructed monoclonal RIAs. We employed methods, solidphase supports, and assay designs similar to our previous studies with soluble antigens such as HBsAg, a-fetoprotein, human chorionic gonadotropin (hCG), and IlhCG (9, (39) (40) (41) (42) (43) (44) (45) . Fig. 4 demonstrates the presence of soluble antigen as shown by high binding activity in cell culture supernatants derived from HCC lines SK-Hep-1 and Mahlavu and rat hepatoma 48 Carlson, Ben-Porath, Shouval, Strauss, Isselbacher, and Wands s:, HTC-4 1. To characterize further the kinetics of the antigenantibody reaction, experiments were performed to assess the effect of temperature on binding activity as shown in Fig. 6 . To our surprise binding activity was enhanced as a function of decreasing and not increasing temperature of incubation. The explanation for this finding is not clear but may be due in part to aggregation of antigen at 40C, which may allow for a multivalent interaction ofthe antibody with a polydeterminant antigen in the RIA (6) . Attempts were made to characterize the nature of the binding activity. As shown in Fig. 7 , a protein of -45,000 mol wt was isolated. It is noteworthy that this protein is similar but not identical in molecular weight to the protein precipitated from '25I-labeled PLC/PRF/5 cells as shown in Fig. 3 We took advantage of some of the physical properties of the anti-HCC monoclonal antibodies to perform in vivo radionuclide-imaging studies. In this regard we studied antibody P215457. Our initial studies focused on coupling P215457 to 99mTc and "'In. We chose these reagents because, for example, 99mTc has an abundant proton emission at 140 keV, physical t,/2 of 6 h, and no beta emission; such characteristics are well matched to present nuclear imaging instruments (46, 47) . The first step involved the coupling of monoclonal antibody to DTPA (48, 49) . The second step required an optimal dithionite concentration for reduction of 99mTcO-and this was chelated to DPTA-coupled monoclonal antibody (50) . Bound and free 99mTc was separated by staphylococcal A affinity chromatography followed by Sephadex G-25 chromatography. In using these procedures, 2-4 mCi of antibody conjugate was available for tail vein injection (100-200 ,uCi/mouse) into nude mice bearing tumors. Although uptake with both 99mTc and "'In was evident in the PLC/PRF/5-induced tumor, substantial uptake was also evident in the liver and spleen (data not shown). Similar results have been observed by others using "'In-and '251-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocellular carcinomas (51) . Because one of our goals is to have the capability to image within the liver, particularly in humans, we elected to abandon this approach.
In an attempt to improve the imaging of human hepatoma in nude mice, P215457 was radiolabeled with 13'I by the lodogen technique to a specific activity varying between 14 and 20 uCi/gg. Animals with tumors were injected with 50-100 ,uCi in 200 ,ul via the tail vein; some of these results are shown in Fig. 8 and Table III . Although antibody uptake within the tumors and subsequent tumor visualization improved compared with the same antibody labeled with "mTc and "'In, the kinetics of tumor uptake with particular reference to the presence of radiolabeled antibody in the blood pool proved to be unsatisfactory. Thus, the slow disappearance of antibody from the blood pool relative to the tumor (animals were followed up to 96 h after tail vein injection) precluded any meaningful imaging results.
Stimulated by the experiments of Larson Table  III and Fig. 9 there was rapid uptake within the tumor at 10 h (Fig. 9 A) . Indeed, after rapid clearance of '25I-P215457 Fab from the blood, there is clear localization of tumor by 24 h ( Fig. 9 C) ; biodistribution experiments confirmed the imaging results (Table III) . Particularly noteworthy was a ratio of -9:1 when comparing uptake of antibody into tumor versus the liver. These results have led us to believe that the Fab fragment of P215457 may be a potent reagent for tumor localization within the liver in vivo.
There is little information regarding the properties of transformed hepatocytes. HCC appears to be one of the most common tumors in the world today. Indeed, projections from epidemiologic data on chronic hepatitis B carriers in Taiwan, suggests that a male has a 50% and female 20% chance of developing such tumors during their lifetime assuming the HBV infection was acquired at birth (1) . In that it is estimated that there are 200-300 million chronic HBV carriers in the world (53), a need to understand the antigenic characteristics of this malignancy better and devise potential strategies for early immunodiagnosis clearly exists. In the present report we have demonstrated that monoclonal antibodies produced against transformed human hepatocytes may be useful in this regard. We are optimistic that such an approach will be helpful in the study of hepatocellular carcinoma in humans.
